5.94
price down icon3.57%   -0.22
pre-market  プレマーケット:  5.95   0.010   +0.17%
loading
前日終値:
$6.16
開ける:
$6.1
24時間の取引高:
647.70K
Relative Volume:
0.70
時価総額:
$317.24M
収益:
$89.04M
当期純損益:
$-241.08M
株価収益率:
-1.1293
EPS:
-5.26
ネットキャッシュフロー:
$-194.72M
1週間 パフォーマンス:
+9.80%
1か月 パフォーマンス:
-15.14%
6か月 パフォーマンス:
-43.96%
1年 パフォーマンス:
-65.12%
1日の値動き範囲:
Value
$5.91
$6.308
1週間の範囲:
Value
$5.15
$6.8299
52週間の値動き範囲:
Value
$5.035
$17.52

Regenxbio Inc Stock (RGNX) Company Profile

Name
名前
Regenxbio Inc
Name
セクター
Healthcare (1151)
Name
電話
240-552-8181
Name
住所
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
職員
344
Name
Twitter
@REGENXBIO
Name
次回の収益日
2025-03-04
Name
最新のSEC提出書
Name
RGNX's Discussions on Twitter

RGNX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RGNX
Regenxbio Inc
5.94 317.24M 89.04M -241.08M -194.72M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.10 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.16 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
596.20 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
234.56 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
230.98 26.16B 3.81B -644.79M -669.77M -6.24

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-11 ダウングレード Goldman Buy → Neutral
2025-02-07 再開されました Raymond James Outperform
2024-11-15 再開されました Morgan Stanley Overweight
2024-10-10 再開されました Raymond James Outperform
2024-06-07 開始されました Goldman Buy
2024-03-11 開始されました H.C. Wainwright Buy
2024-03-08 アップグレード RBC Capital Mkts Sector Perform → Outperform
2024-03-06 アップグレード Leerink Partners Market Perform → Outperform
2024-02-21 再開されました Raymond James Outperform
2023-11-01 開始されました Stifel Buy
2023-06-02 開始されました Robert W. Baird Outperform
2022-06-23 開始されました Berenberg Buy
2021-12-15 開始されました Wedbush Neutral
2021-10-19 再開されました Morgan Stanley Overweight
2021-01-06 アップグレード Raymond James Outperform → Strong Buy
2020-12-16 開始されました UBS Buy
2020-06-25 再開されました BofA/Merrill Buy
2020-05-13 開始されました RBC Capital Mkts Sector Perform
2019-08-20 アップグレード SVB Leerink Underperform → Mkt Perform
2019-06-18 繰り返されました Chardan Capital Markets Buy
2019-06-14 再開されました Raymond James Outperform
2019-06-05 繰り返されました Chardan Capital Markets Buy
2019-02-25 アップグレード Evercore ISI In-line → Outperform
2019-02-05 アップグレード Raymond James Outperform → Strong Buy
2018-12-17 繰り返されました Chardan Capital Markets Buy
2018-11-08 繰り返されました BofA/Merrill Neutral
2018-08-08 繰り返されました Chardan Capital Markets Buy
2018-07-23 ダウングレード BofA/Merrill Buy → Neutral
2018-07-10 繰り返されました Chardan Capital Markets Buy
2018-05-09 繰り返されました Barclays Overweight
2018-04-09 繰り返されました Chardan Capital Markets Buy
2018-03-12 ダウングレード Evercore ISI Outperform → In-line
2018-02-13 開始されました Mizuho Neutral
2017-11-09 再開されました Morgan Stanley Overweight
すべてを表示

Regenxbio Inc (RGNX) 最新ニュース

pulisher
Apr 17, 2025

Vanguard Group Inc. Trims Stake in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat

Apr 17, 2025
pulisher
Apr 08, 2025

RGNX stock touches 52-week low at $5.6 amid sharp annual decline - Investing.com Nigeria

Apr 08, 2025
pulisher
Apr 07, 2025

RGNX stock touches 52-week low at $5.6 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 02, 2025

When (RGNX) Moves Investors should Listen - news.stocktradersdaily.com

Apr 02, 2025
pulisher
Mar 31, 2025

Clear Street sets Regenxbio stock Buy rating, $50 target By Investing.com - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

Clear Street sets Regenxbio stock Buy rating, $50 target - Investing.com India

Mar 31, 2025
pulisher
Mar 26, 2025

5 Reasons To Buy Regenxbio Right Now (NASDAQ:RGNX) - Seeking Alpha

Mar 26, 2025
pulisher
Mar 21, 2025

REGENXBIO partners with Nippon Shinyaku for MPS therapies - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing - insights.citeline.com

Mar 21, 2025
pulisher
Mar 21, 2025

RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating - TipRanks

Mar 21, 2025
pulisher
Mar 20, 2025

REGENXBIO’s DMD Gene Therapy RGX-202 Generates Microdystrophin Expression in Additional Patients Treated in Phase 1/2 Trial - CGTLive™

Mar 20, 2025
pulisher
Mar 20, 2025

Regenxbio Rises After Duchenne Update And Sarepta Safety Scare - insights.citeline.com

Mar 20, 2025
pulisher
Mar 20, 2025

Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN

Mar 20, 2025
pulisher
Mar 20, 2025

Regenxbio’s RGX-202 continues to show promise in DMD - The Pharma Letter

Mar 20, 2025
pulisher
Mar 20, 2025

Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old - Clinical Trials Arena

Mar 20, 2025
pulisher
Mar 20, 2025

Regenxbio stock target raised to $29 at Raymond James By Investing.com - Investing.com Canada

Mar 20, 2025
pulisher
Mar 19, 2025

REGENXBIO reports promising gene therapy trial results By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Baird maintains Regenxbio stock outperform rating, $39 target By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Baird maintains Regenxbio stock outperform rating, $39 target - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Regenxbio stock target raised to $29 at Raymond James - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Regenxbio up 4% following additional data on Duchenne gene therapy asset - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial - Benzinga

Mar 19, 2025
pulisher
Mar 19, 2025

Regenxbio Says New Data Support Potential Gene Therapy for Duchenne Muscular Dystrophy - MarketScreener

Mar 19, 2025
pulisher
Mar 19, 2025

REGENXBIO reports promising gene therapy trial results - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

REGENXBIO: New Interim Data Reinforces Potential Of RGX-202Quick Facts - Nasdaq

Mar 19, 2025
pulisher
Mar 19, 2025

Breakthrough: REGENXBIO DMD Gene Therapy Achieves Unprecedented 122% Protein Expression - StockTitan

Mar 19, 2025
pulisher
Mar 18, 2025

Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 18, 2025

Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements By Investing.com - Investing.com Canada

Mar 18, 2025
pulisher
Mar 17, 2025

H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy By Investing.com - Investing.com Philippines

Mar 17, 2025
pulisher
Mar 17, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy - Investing.com India

Mar 17, 2025
pulisher
Mar 15, 2025

Regenxbio completes its BLA filing for first potential gene therapy for MPS II - The Pharma Letter

Mar 15, 2025
pulisher
Mar 15, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 15, 2025
pulisher
Mar 14, 2025

REGENXBIO Earnings Call Highlights Strategic Progress - TipRanks

Mar 14, 2025
pulisher
Mar 14, 2025

Earnings call transcript: Regenxbio Q4 2024 beats EPS forecast, stock surges - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Stifel maintains Buy on Regenxbio stock, $40 target By Investing.com - Investing.com South Africa

Mar 14, 2025
pulisher
Mar 14, 2025

Stifel maintains Buy on Regenxbio stock, $40 target - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

A Glimpse Into The Expert Outlook On Regenxbio Through 5 Analysts - Benzinga

Mar 14, 2025
pulisher
Mar 14, 2025

Regenxbio Inc earnings beat by $0.12, revenue fell short of estimates - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience - Yahoo Canada Finance

Mar 14, 2025
pulisher
Mar 14, 2025

REGENXBIO Reports Progress in Gene Therapy Pipeline - TipRanks

Mar 14, 2025

Regenxbio Inc (RGNX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.04
price up icon 2.51%
$72.65
price up icon 3.49%
$32.60
price up icon 1.27%
$24.61
price up icon 6.77%
$98.76
price up icon 0.52%
biotechnology ONC
$230.98
price up icon 1.24%
大文字化:     |  ボリューム (24 時間):